Facchinetti F - Search Results

1

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.

Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. Berchuck JE, et al. Among authors: facchinetti f. Ann Oncol. 2022 Dec;33(12):1269-1283. doi: 10.1016/j.annonc.2022.09.150. Epub 2022 Sep 9. Ann Oncol. 2022. PMID: 36089135 Free article.

2

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

Facchinetti F, Caramella C, Auger N, Planchard D, Adam J, Lacroix L, Remon J, Massard C, Soria JC, Friboulet L, Besse B. Facchinetti F, et al. Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000520. Tumori. 2016. PMID: 27197808

3

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Facchinetti F, Rossi G, Bria E, Soria JC, Besse B, Minari R, Friboulet L, Tiseo M. Facchinetti F, et al. Cancer Treat Rev. 2017 Apr;55:83-95. doi: 10.1016/j.ctrv.2017.02.010. Epub 2017 Mar 12. Cancer Treat Rev. 2017. PMID: 28342334 Review.

4

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F. Lindsay CR, et al. Among authors: facchinetti f. Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156. Ann Oncol. 2017. PMID: 28633480 Free article.

5

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC. Ricordel C, et al. Among authors: facchinetti f. Ann Oncol. 2018 Jan 1;29(suppl_1):i28-i37. doi: 10.1093/annonc/mdx705. Ann Oncol. 2018. PMID: 29462256 Free article. Review.

6

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D. Leonetti A, et al. Among authors: facchinetti f. Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Cancer Treat Rev. 2018. PMID: 29729495 Review.

7

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

Facchinetti F, Friboulet L. Facchinetti F, et al. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S103-S106. doi: 10.21037/tlcr.2018.02.04. Transl Lung Cancer Res. 2018. PMID: 29782561 Free PMC article. No abstract available.

8

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC. Ricordel C, et al. Among authors: facchinetti f. Ann Oncol. 2019 May 1;30(5):858. doi: 10.1093/annonc/mdy222. Ann Oncol. 2019. PMID: 29982319 Free article. No abstract available.

9

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Recondo G, et al. Among authors: facchinetti f. Nat Rev Clin Oncol. 2018 Nov;15(11):694-708. doi: 10.1038/s41571-018-0081-4. Nat Rev Clin Oncol. 2018. PMID: 30108370 Review.

10

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.

Facchinetti F, Friboulet L. Facchinetti F, et al. Lung Cancer (Auckl). 2019 Sep 9;10:87-94. doi: 10.2147/LCTT.S190786. eCollection 2019. Lung Cancer (Auckl). 2019. PMID: 31572036 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

753 results

Search Page